Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.

Clinical trial NCT04904237 · UNKNOWN

Trial details

NCT number: NCT04904237
Sponsor: Shanghai Jiao Tong University School of Medicine
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Acute Myeloid Leukemia

Start date: 2021-01-01
Primary completion: 2024-01-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.